Prof Donal Brennan has been named chair of Ireland’s newly formed Clinical Trials Advisory Council, a move the health ministry says will help expand patient access to cutting‑edge therapies.
Government announces new leadership for clinical trials
Minister for Health Jennifer Carroll MacNeill announced the appointment, noting the council’s role in guiding the nation’s clinical‑trial framework. Brennan, a professor of gynaecological oncology at University College Dublin and a consultant at the Mater Misericordiae University Hospital, previously chaired the National Clinical Trials Oversight Group (NCTOG). In that capacity he oversaw the production of a report titled “Transforming Ireland’s Clinical Trials Setting: A Blueprint for Implementation.” The council will be tasked with turning the blueprint’s recommendations into practice.
Scope and composition of the advisory body
The Department of Health said the council will be finalized in the coming weeks after an extensive expression‑of‑interest campaign. Its membership is expected to include patient representatives, academics, health‑care providers, regulators, industry stakeholders and government officials. By gathering a broad cross‑section of the health‑research ecosystem, they aim to address gaps in trial design, recruitment and regulatory pathways.
Related: What To Know Before Getting Dental Treatments
“Establishing the Clinical Trials Advisory Council represents an important milestone in driving Ireland’s ambition to become a leader across the international clinical trials field,” the minister said. “I am delighted that Donal has agreed to take the helm in steering the process to implement in full the recommendations brought forward by NCTOG.”
The council’s work aligns with Ireland’s broader life‑science agenda. At the EU level, the country is leading negotiations on the EU Biotech Act, a legislative package intended to boost biotechnology and manufacturing across Europe. Domestically, a new National Life Sciences Strategy is being drafted to keep Ireland competitive and to create high‑value jobs.
“This step forward in enhancing clinical trials in Ireland aligns with Ireland’s work at EU level in leading negotiations on the EU Biotech Act and the National Life Sciences Strategy,” the department’s statement added. “As Ireland’s Presidency of the European Council begins, one of the priorities for the health agenda is to support progress of the EU Biotech Act, to strengthen the biotechnology and manufacturing sectors in the EU, particularly in health.”
In a brief statement, Prof Brennan expressed gratitude for the role. “I am very grateful to the Minister for this opportunity, and it will be a privilege to be involved again in continuing the important process we have begun in transforming Ireland’s clinical trials setting,” he said. He added that he looks forward to working with the council, the ministry and other partners to translate the blueprint’s recommendations into measurable improvements.
Related: Improving your smile with your dentist St John’s Wood
Trials could start sooner.
From a practical standpoint, the council’s activity could mean shorter wait times for patients to enroll in trials and more streamlined approval processes for new therapies. If the advisory body succeeds in aligning research priorities with industry capabilities, hospitals may see a rise in trial‑related funding and an influx of advanced treatment options.
Health‑sector observers note that the council’s success will depend on how quickly it can move from consultation to implementation. The blueprint highlighted several bottlenecks, including fragmented data sharing and limited patient outreach. Addressing these issues will require coordination across public and private entities, as well as sustained commitment from policymakers.
While the council’s full roster remains pending, the inclusion of patient voices is a notable feature. Engaging those who stand to benefit directly from clinical research can help shape trial designs that are more patient‑centred and improve recruitment rates.
Related: Beautiful, healthy teeth with your dentist Meath
Stakeholders anticipate that the council will also interface with the EU Biotech Act negotiations, ensuring that Ireland’s domestic policies are compatible with broader European standards. This alignment could make the country a more attractive destination for multinational pharma and biotech firms seeking to conduct trials.
“The work of CTAC aligns with our current leadership role at EU level in leading negotiations on the Biotech Act and will ultimately drive improvements across Ireland’s clinical trials field to achieve better health outcomes for patients, enhance Ireland’s reputation and support the wider economy,” the minister said.
As the council’s members are confirmed, the Department of Health plans to release a detailed work plan outlining priorities, timelines and performance metrics. The aim is to provide transparency and allow public monitoring of progress toward the goals set out in the NCTOG blueprint.
